Postdoctoral Position: Characterization And Functional Validation Of Epigenetic Changes Implicated...

Universities and Institutes of France


October 31, 2021


  • Organisation/Company: CEA - Centre National de Recherche en Genomique
  • Research Field: Biological sciences › Biology Chemistry › Biochemistry Medical sciences
  • Researcher Profile: First Stage Researcher (R1) Recognised Researcher (R2) Established Researcher (R3) Leading Researcher (R4)
  • Application Deadline: 31/10/2021 00:00 - Europe/Brussels
  • Location: France › Evry
  • Type Of Contract: Temporary
  • Job Status: Full-time
  • Offer Starting Date: 15/11/2021
  • Breast Cancer (BC) is the first cause of cancer-related death in women worldwide. Breast cancer is classified into well recognized molecular subtypes. Despite solid pre-clinical evidence, only some patients benefit from administering drug combinations, an indication that patient and tumor heterogeneity is still present in the current stratification. Out of the numerous possible combinations of approved drugs, only a few have been actually tried, and the choice of tested combinations has been to some degree arbitrary. The EU H2020 funded project RESCUER (Resistance under combinatorial treatment in ER+ and ER- breast cancer) seeks to develop new approaches and identify mechanisms of treatment resistance at systems level, exploring how the effectiveness of specific targeted therapies applied in different clinical trials is affected by patient- and tumor-specific conditions. For this purpose, the project will gather and integrate multidimensional data from ongoing clinical trials to discover molecular signatures of resistance and predict patient response to combinatorial therapies. The overreaching goal is to develop computer “xenograft model” as a cost-efficient and better alternative in terms of ethics, availability to everyone, and animal use.

    In the framework of the RESCUER project, the Laboratory for Epigenetics and Environment of the CEA – CNRGH will identify and functionally validate epigenetic changes in tumor-relevant immune cell populations correlating and potentially predicting treatment response in breast cancer patients in current cancer immunotherapy trials.

    Offer Requirements Specific Requirements

    The candidate must have a PhD in immunology, molecular biology or cellular biology. The candidate should have a solid background in immunology and experience in the use of flow cytometry-based cell sorting and cell culture of primary human cells. Knowledge on genomic technologies such as NGS including library preparation as well as some competence in analyzing data from NGS experiments is a strong asset. The candidate should have good communication skills and be fluent in English to interact with the other partners of the European consortium participating in the described tasks, have good reporting capabilities and be motivated to learn and implement new cutting-edge technologies in partner laboratories (e.g. culture, treatment and analysis of tumor explants).

    Contact Information
  • Organisation/Company: CEA - Centre National de Recherche en Genomique
  • Organisation Type: Public Research Institution
  • Website: https://
  • Country: France
  • Similar Jobs

    Luxembourg Institute of Health

    Luxembourg 4 days ago

    Add to favorites

    Senior Postdoctoral Researcher in Immuno-Oncology - BJ0921

    group is conducting oncology research at the forefront of translating basic research knowledge in the field of immuno-oncology into clinical applications. research activities depends on establishing collaboration with pharma immunotherapies by extending their use to...

    University of Bern

    Switzerland 5 days ago

    Add to favorites

    PhD student position to study DNA damage response in the context of cancer therapy resistance

    PhD student position to study DNA damage response in the context of cancer This PhD student position is available at the University of Bern, Switzerland, to join the research group of Sven Rottenberg (Vetsuisse Faculty...